LYTIR

Insider · SEC Form 4 · Chief Financial Officer

Hyep Ivan

In the 12 months to Nov 8, 2026, on the open market: sold $1.2M of BCAX. Filed a median of 2 business days after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $1.2M in total.Jul: Insider sales $808KAug: Insider sales $350KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $1.2M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. BCAXSold: Bicara Therapeutics Inc. Aug 10, 2026 12,500 shares filed Aug 12, 2026 129,855 shares held directly after, as filed 10b5-1 plan filing $350K
  2. BCAXSold: Bicara Therapeutics Inc. Jul 8, 2026 28,000 shares filed Jul 10, 2026 3 transactions 10b5-1 plan filing $808K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • BCAX: option exercise or conversion (code M), 2 entries, Jul 8 to Aug 10, 2026
Code M
An exercise or conversion of a derivative security received from the company, such as stock options.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.